Roquefort Therapeutics (LON:ROQ) Trading 46.3% Higher – Here’s Why

Roquefort Therapeutics plc (LON:ROQ)’s stock price traded up 46.3% during mid-day trading on Monday . The company traded as high as GBX 1.80 ($0.02) and last traded at GBX 1.80 ($0.02). 1,490,235 shares changed hands during trading, a decline of 30% from the average session volume of 2,131,692 shares. The stock had previously closed at GBX 1.23 ($0.02).

Roquefort Therapeutics Stock Up 46.3%

The business has a 50 day moving average of GBX 1.61 and a 200-day moving average of GBX 2.25. The stock has a market cap of £2.29 million, a PE ratio of -1.49 and a beta of 0.05. The company has a current ratio of 0.79, a quick ratio of 3.07 and a debt-to-equity ratio of 12.37.

Roquefort Therapeutics (LON:ROQ) last posted its quarterly earnings data on Wednesday, April 30th. The company reported GBX (0.75) (($0.01)) earnings per share for the quarter. Roquefort Therapeutics had a negative return on equity of 29.57% and a negative net margin of 57,057.07%.

Insiders Place Their Bets

In related news, insider Simon Sinclair acquired 72,507 shares of the firm’s stock in a transaction on Friday, June 27th. The stock was bought at an average cost of GBX 1 ($0.01) per share, with a total value of £725.07 ($990.13). Insiders own 60.40% of the company’s stock.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.